Navigation Links
NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share
Date:7/10/2014

BEDFORD, Mass., June 30, 2014 /PRNewswire/ -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics software and services, previously announced on June 26, 2014 that its Board of Directors had declared a special cash dividend of $1.75 per share, or approximately $40 million in total.  The Board established a record date of July 10, 2014 and a payment date of July 24, 2014.  The Company was subsequently notified by NASDAQ that it had set an ex-dividend date for this special cash dividend.  An ex-dividend date of July 25, 2014 has been established by NASDAQ.

We encourage shareholders to contact their brokers in order to understand the Nasdaq Rules and Regulations regarding the effect of selling shares of our common stock following the record date on their eligibility to receive the dividend.

About Aware
Aware is a leading provider of biometrics software products and development services to governments, system integrators, and solution providers globally. Our products include SDKs, software components, workstation applications, and a modular, centralized, service-oriented platform. They fulfill a broad range of functions critical to biometric authentication and search, including face, fingerprint, and iris autocapture, image quality assurance, data compliance, capture hardware peripheral abstraction, centralized data processing and workflow, subsystem connectivity, and biometric matching algorithms. The products are used to enable identity-centric security solutions with biometrics for applications including border management, credentialing and access control, intelligence and defense, and law enforcement. Aware is a publicly held company (Nasdaq: AWRE) based in Bedford, Massachusetts.

We refer you to
'/>"/>

SOURCE Aware, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. NASDAQ Sets Ex-Dividend Date for Aware, Inc.s Special Cash Dividend of $1.80 Per Share
2. Dynasil Regains Compliance with NASDAQ Listing Requirements
3. Aware, Inc. Reports First Quarter 2012 Financial Results
4. Aware, Inc. Reports Second Quarter 2012 Financial Results
5. Aware, Inc. Reports Third Quarter 2012 Financial Results
6. Aware, Inc. Declares Special Cash Dividend of $1.80 Per Share, or Approximately $40 Million in Total
7. Aware, Inc. Reports First Quarter 2013 Financial Results
8. Aware, Inc. Reports Second Quarter 2013 Financial Results
9. Aware, Inc. Reports Third Quarter 2013 Financial Results
10. Patient in vegetative state not just aware, but paying attention
11. Dinosaur fossil: Even specialized predators didnt turn down free meals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
(Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2
... of copying the body’s own natural "waste disposal" chemistry to ... percent of patients with urea cycle disorders --- most of ... New England Journal of Medicine summarizing a quarter century of ... phenylacetate and sodium benzoate, two chemicals the body already makes ...
... the government of The Gambia is encouraging citizens living ... to try an unproven herbal remedy. The HIV Medicine ... his unproven claims that the treatment "cures" AIDS. ... treatment to a handful of patients who had been ...
... isn’t such a good thing after all. , ... say they have confirmed what other scientists have only ... can help build stronger immune systems, and may protect ... that infants who were exposed to high levels of ...
Cached Biology News:An 'elegant' idea proves its worth 25 years later 2HIVMA opposes The Gambia's unproven AIDS remedy 2Early exposure to indoor fungus molecules may protect infants against future allergies 2
(Date:11/27/2014)... The Europe Thermal Protective Clothing market ... crucial revenue forecasts. It estimates the market to ... CAGR of 7.5%, from 2013 to 2018. , ... Protective Clothing market report for a glimpse of ... various tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html ...
(Date:11/27/2014)... -- First articles published now available ... Elsevier , a world-leading provider of scientific, technical and ... the launch of a new journal: Extreme ... launch of Extreme Mechanics Letters is driven ... applied sciences such as micro and nanotechnologies, biotechnologies, soft ...
(Date:11/26/2014)... 2014 (PRWEB) November 26, 2014 Publicis ... network, today announced the organization has won a total ... Awards. Digitas Health LifeBrands was honored with a Silver ... PHCG agencies received eight Awards of Excellence. , ... of pharmaceutical advertising and promotion. The Awards provide a ...
(Date:11/26/2014)... November 26, 2014 The North ... segments the market for detailed analysis of the ... market to reach $616.3 million by 2018, growing ... 2018. , Browse through the TOC of the ... get an idea of the in-depth analysis and ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3
... Loramyc(R) Completes Patient Enrollment Ahead ... Zensana(TM) Reformulation Complete, Resubmission on Target, WOODCLIFF ... (NYSE: PRX ) today provided an update ... pipeline,products: pafuramidine, Loramyc(R) (miconazole Lauriad(R)), and Zensana(TM),(ondansetron). These ...
... Schering-Plough,Corporation (NYSE: SGP ) will provide a ... Hassan, chairman and chief executive officer, followed,by a ... Conference on Jan. 3, 2008, at approximately 8:45 ... "unplugged" presentation., Included in Mr. Hassan,s comments ...
... Schering-Plough,Corporation (NYSE: SGP ) is scheduled to ... quarter and full year on Tuesday, Feb. 12,2008., ... conduct a conference,call to review results for the 2007 ... and CEO, and other members of management,will host the ...
Cached Biology Technology:Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 2Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 3Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 4Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 5Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference 2Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result 2